Celldex: First Patient Dosed in Phase 2 Study of Barzolvolimab in PN
The first patient has been dosed in Celldex Therapeutics, Inc.’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast […]